PMID- 33083644
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2452-1094 (Print)
IS  - 2452-1094 (Electronic)
IS  - 2452-1094 (Linking)
VI  - 5
IP  - 5
DP  - 2020 Sep-Oct
TI  - Quantitative 3-Dimensional Photographic Assessment of Breast Cosmesis After Whole 
      Breast Irradiation for Early Stage Breast Cancer: A Secondary Analysis of a 
      Randomized Clinical Trial.
PG  - 824-833
LID - 10.1016/j.adro.2020.04.035 [doi]
AB  - PURPOSE: Our purpose was to use 3-dimensional (3D) surface photography to 
      quantitatively measure breast cosmesis within the framework of a randomized 
      clinical trial of conventionally fractionated (CF) and hypofractionated (HF) 
      whole breast irradiation (WBI); to identify how 3D measurements are associated 
      with patient- and physician-reported cosmesis; and to determine whether objective 
      measures of breast symmetry varied by WBI treatment arm or transforming growth 
      factor beta 1 (TGFbeta1) status. METHODS AND MATERIALS: From 2011 to 2014, 287 women 
      age >/=40 with ductal carcinoma in situ or early-stage invasive breast cancer were 
      enrolled in a multicenter trial and randomized to HF-WBI or CF-WBI with a boost. 
      Three-dimensional surface photography was performed at 3 years posttreatment. 
      Patient-reported cosmetic outcomes were recorded with the Breast Cancer Treatment 
      Outcome Scale. Physician-reported cosmetic outcomes were assessed by the 
      Radiation Therapy Oncology Group scale. Volume ratios and 6 quantitative measures 
      of breast symmetry, termed F1-6C, were calculated using the breast contour and 
      fiducial points assessed on 3D surface images. Associations between all metrics, 
      patient- and physician-reported cosmesis, treatment arm, and TGFbeta1 genotype were 
      performed using the Kruskal-Wallis test and multivariable logistic regression 
      models. RESULTS: Among 77 (39 CF-WBI and 38 HF-WBI) evaluable patients, both 
      patient- and physician-reported cosmetic outcomes were significantly associated 
      with the F1C vertical symmetry measure (both P < .05). Higher dichotomized F1C 
      and volumetric symmetry measures were associated with improved patient- and 
      physician-reported cosmesis on multivariable logistic regression (both P </= .05). 
      There were no statistically significant differences in vertical symmetry or 
      volume measures between treatment arms. Increased F6C horizontal symmetry was 
      observed in the CF-WBI arm (P = .05). Patients with the TGFbeta1 C-509T variant 
      allele had lower F2C vertical symmetry measures (P = .02). CONCLUSIONS: 
      Quantitative 3D image-derived measures revealed comparable cosmetic outcomes with 
      HF-WBI compared with CF-WBI. Our findings suggest that 3D surface imaging may be 
      a more sensitive method for measuring subtle cosmetic changes than global 
      patient- or physician-reported assessments.
CI  - (c) 2020 The Authors.
FAU - Chapman, Bhavana V
AU  - Chapman BV
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas.
FAU - Lei, Xiudong
AU  - Lei X
AD  - Health Services Research, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Patil, Prithvi
AU  - Patil P
AD  - Department of Engineering Technology, University of Houston, Houston, Texas.
AD  - The University of Texas Health Science Center at Houston, Houston, Texas.
FAU - Tripathi, Shikha
AU  - Tripathi S
AD  - Department of Engineering Technology, University of Houston, Houston, Texas.
FAU - Nicklaus, Krista M
AU  - Nicklaus KM
AD  - Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
AD  - Department of Biomedical Engineering, The University of Texas at Austin, Austin, 
      Texas.
FAU - Grossberg, Aaron J
AU  - Grossberg AJ
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas.
AD  - Department of Radiation Medicine, Oregon Health and Science University, Portland, 
      Oregon.
FAU - Shaitelman, Simona F
AU  - Shaitelman SF
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas.
FAU - Thompson, Alastair M
AU  - Thompson AM
AD  - Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
AD  - Department of Surgery, Division of Surgical Oncology, Baylor College of Medicine, 
      Houston, Texas.
FAU - Hunt, Kelly K
AU  - Hunt KK
AD  - Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Buchholz, Thomas A
AU  - Buchholz TA
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas.
AD  - Scripps MD Anderson Cancer Center, La Jolla, California.
FAU - Merchant, Fatima
AU  - Merchant F
AD  - Department of Engineering Technology, University of Houston, Houston, Texas.
AD  - Department of Biomedical Engineering, The University of Texas at Austin, Austin, 
      Texas.
AD  - Department of Computer Science, University of Houston, Houston, Texas.
FAU - Markey, Mia K
AU  - Markey MK
AD  - Department of Biomedical Engineering, The University of Texas at Austin, Austin, 
      Texas.
AD  - Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, 
      Texas.
FAU - Smith, Benjamin D
AU  - Smith BD
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas.
AD  - Health Services Research, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Reddy, Jay P
AU  - Reddy JP
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA143190/CA/NCI NIH HHS/United States
GR  - R01 CA225646/CA/NCI NIH HHS/United States
GR  - R01 CA203984/CA/NCI NIH HHS/United States
GR  - R01 CA207216/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200521
PL  - United States
TA  - Adv Radiat Oncol
JT  - Advances in radiation oncology
JID - 101677247
PMC - PMC7557136
EDAT- 2020/10/22 06:00
MHDA- 2020/10/22 06:01
PMCR- 2020/05/21
CRDT- 2020/10/21 06:05
PHST- 2020/03/28 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/10/21 06:05 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/10/22 06:01 [medline]
PHST- 2020/05/21 00:00 [pmc-release]
AID - S2452-1094(20)30131-7 [pii]
AID - 10.1016/j.adro.2020.04.035 [doi]
PST - epublish
SO  - Adv Radiat Oncol. 2020 May 21;5(5):824-833. doi: 10.1016/j.adro.2020.04.035. 
      eCollection 2020 Sep-Oct.